Worldwide cancer drug sales are already way ahead of other drug classes, and the revenue generated by them is expected to grow even larger over the coming years. This is according to data by Statista Market Insights. (Reported on 14 October 2026).
Oncology drugs are expected to reach US$ 232.5 billion in sales in 2026, more than double the next item on the list, anti-diabetic drugs, at almost US$ 93 billion. As GLP-1 shots developed for diabetes but used for weight loss are booming, the segment experienced another push and overtook vaccines, which are expected to earn US$ 65.5 billion dollars in sales this year, down from peaks during the coronavirus pandemic.
Another drug class growing in sales is immunosuppressants, expected to bring in revenues of US$ 72 billion this year. Psychiatric drugs are meanwhile expected to become the seventh-biggest drug class globally, up from the eighth-biggest currently.
By 2031, cancer drug sales are expected to reach US$ 311 billion annually. Considering worldwide drug sales, cancer drugs are expected to approach 20% of the market that year.
Cancer drugs are extremely pricey and therefore generate high revenues, with the cost of cancer treatment at above US$ 100,000 per patient (in some regions). Cancer rates themselves are also rising due to longer lifespans. Money funnelled into cancer research means new medications are released, which improves cancer treatment but likely also increases its price as pharmaceutical companies charge a premium for newly researched and released drugs.
Editor’s note – As discussed at the Packaging South Asia Conference in Mumbai on 9th October by Dr Keshav Kumar, cancer drugs and biologics drugs are also particularly prone to counterfeiting in various markets because of their high value.
